NSE: CONCORDBIO · 4 November 2026
- Concord Biotech has risen 12.61% over 2 trading sessions; today's move is -46.62%.
- Concord Biotech informed the exchanges that the Board of Directors fixed Wednesday, November 04, 2026, as the record date for determining shareholders eligible to receive bonus equity shares in the ratio of 1:1. This corporate action follows approvals secured through a postal ballot process completed in late October 2026.
- Trading volume was 1.29 times the 20-day average daily volume.
Concord Biotech share price: 12.61% rise over 2 trading sessions
Concord Biotech Ltd. shares dropped sharply today, plunging by -46.62% to settle at ₹655.50. The stock experienced extreme volatility, moving within an intraday range of ₹594.60 on the low side and reaching a high of ₹662.00 after opening at ₹610.00.
In broader market comparison, the benchmark Nifty index rose by 0.63%, and the sectoral Nifty Pharma index advanced by 0.42% during the session. Concord Biotech's sharp downward movement contrasted with the positive trend observed across the broader healthcare and pharmaceutical sector. Over the trailing periods, the stock had registered a 5-day return of 3.29% and a 20-day return of -4.28%.
Company disclosures from recent weeks show corporate actions, notably the fixing of November 04, 2026, as the record date for a 1:1 bonus share issue approved following a postal ballot. Additionally, the company reported its financial results for the period ended September 30, 2026, showing consolidated revenue of ₹309.1 crores and a profit after tax of ₹69.6 crores. While these operational updates and corporate actions provide fundamental context, the sharp downward price movement today occurred independently of any single newly announced adverse regulatory or earnings catalyst for the session.
3.56 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.76 lakh shares (1.29 times). The five-day average daily volume was 5.62 lakh shares. Separately, the NSE report for 4 November 2026 showed 1.02 lakh shares delivered, representing 28.67% of that day’s traded volume. The same report recorded 33,428 trades.
The sharp decline of -46.62% occurred with volume exceeding the 20-day average by 1.29 times, though no single adverse regulatory filing or negative corporate disclosure was released on the session date to directly account for the move.
Latest Company Developments
Concord Biotech informed the exchanges that the Board of Directors fixed Wednesday, November 04, 2026, as the record date for determining shareholders eligible to receive bonus equity shares in the ratio of 1:1. This corporate action follows approvals secured through a postal ballot process completed in late October 2026.
Bonus issuances expand the paid-up share capital base and adjust per-share pricing metrics while reflecting management confidence in long-term stability.
The company submitted its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Consolidated revenue from operations stood at ₹309.1 crores, accompanied by an EBITDA of ₹104.4 crores and a profit after tax of ₹69.6 crores for the quarter.
Quarterly earnings figures serve as the primary baseline for institutional evaluations of revenue growth, segment performance, and operating margins.
Concord Biotech announced the successful completion of a USFDA inspection at its Unit II formulation facility located in Valthera, Ahmedabad. The inspection concluded with one minor procedural observation that was unrelated to good manufacturing practices.
Successful regulatory inspections validate compliance standards and ensure uninterrupted international supply continuity across regulated export markets.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Concord Biotech Limited has informed the Exchange that Record date for the purpose of Bonus is 04-Nov-2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Research & Brokerage Views
Citi reinitiated coverage on Concord Biotech with a Neutral rating, highlighting moderating growth trends within the active pharmaceutical ingredient segment.
Historical Bulk / Block Deals
What to Watch Next
- Post-bonus adjustment trading dynamics and liquidity following the November 4 record date
- Execution of the product pipeline and ramp-up of the newly launched Inspira dermatology division
- Export market performance across regulated geographies and future USFDA audit updates
- Quarterly margin trends relative to raw material cost fluctuations and product mix changes
Other Dated Coverage
- Concord Biotech Share Price Today: Falls 10.56% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
- Concord Biotech Share Price Falls 8.17% Intraday, Closes 7.77% Lower | 28 October 2026 — 28 October 2026
- Concord Biotech Share Price Today: Rises 11.88% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech informed the exchanges that the Board of Directors fixed Wednesday, November 04, 2026, as the record date for determining shareholders eligible to receive bonus equity shares in the ratio of 1:1. This corporate action follows approvals secured through a postal ballot process completed in late October 2026.
How strong was Concord Biotech’s trading volume?
3.56 lakh shares traded, 1.29 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.